Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.70 |
| ▸ | CCR8 | P51685 | 1/20 | 0.70 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 3/20 | 0.41 |
| ▸ | NOS2 | P35228 | 3/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26751431 | 0.93 | CCR1 (0.73) | CCR1CCR8METAP2TGFBR1CYP2A6 | |
| SCHEMBL3027281 | 0.84 | CCR1 (0.55) | CCR1CCR8TGFBR1NOS3NOS2 | |
| SCHEMBL196966 | 0.83 | CCR1 (1.00) | CCR1CCR8METAP2TGFBR1CYP2A6 | |
| SCHEMBL30511194 | 0.83 | CCR1 (1.00) | CCR1CCR8METAP2TGFBR1CYP2A6 | |
| SCHEMBL29388304 | 0.83 | CCR1 (1.00) | CCR1CCR8METAP2TGFBR1CYP2A6 | |
| SCHEMBL3084862 | 0.83 | NOS3 (0.55) | CCR1CCR8NOS3NOS2NOS1 | |
| SCHEMBL29648194 | 0.83 | NOS3 (0.55) | CCR1CCR8NOS3NOS2NOS1 | |
| SCHEMBL29751933 | 0.81 | CCR1 (0.94) | CCR1CCR8METAP2TGFBR1CYP2A6 | |
| SCHEMBL22854565 | 0.81 | NOS3 (0.52) | CCR1CCR8NOS3NOS2NOS1 | |
| SCHEMBL20557390 | 0.81 | CCR1 (0.94) | CCR1CCR8METAP2TGFBR1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-20140045873-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045873-A1 | NOVEL MICROBIOCIDES | MSR1, CD209, C3AR1 | CCR1 202/4885CCR8 831/4885METAP2 374/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | CCR1 2384/4885CCR8 2508/4885METAP2 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.